5. Guía sobre la transfusión de componentes sanguíneos y derivados plasmáticos. Sociedad Española de Transfusión Sanguínea. 3 ra. ed. Madrid: Editorial Salvat S.A.;2007.
6. Beris P, Muñoz M, García-Erce JA, Thomas D, Maniatis A, Van der Linden P. Perioperative anemia management: consensus statement on the role of intravenous iron. Br J Anaesth. 2008; 100:599-604.
7. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N Engl J Med. 2007; 356:2301-11.
8. Levy JH. Pharmacological methods to reduce perioperative bleeding. Transfusion. 2008; 48 (1Supl.II):31-8.
9. Brown JR, Birkmeyer NJ, O’Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801-2813.
10. Mangano DT, Miao Y, Vuylsteke A, Tudor IC, Juneja R, Filipescu D, et. al. Investigators of The Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery. JAMA. 2007; 297:471-9.
11. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et. al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med. 2008; 358:2319-31.
12. Despotis G, Eby C, Lublin DM. A review of transfusion risks and optimal management of perioperative bleeding with cardiac surgery. Transfusion 2008;48 (1Supl.II):2-30.
13. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn D. Recommendations on the use of recombinant activated factor VII as an adjuntive treatment for massive bleeding. A European perspective. Critical Care. 2008; 10:120.
14. Mangano DT, Tudor IC, Dietzel C. Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med. 2008; 354:353-365.
15. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. N Engl J Med. 2006; 355:1303-5.
16. International Standard Randomised Controlled Trial Number Register: registered number ISRCTN15166455. (Accessed May 7, 2008, at http://controlled-trials/. com/ISRCTN.)
17. Novo Nordisk stock exchange announcement. (Accessed May 7, 2008, at http://www.novo nordisk. com/press/ sea/sea.asp.)
18. Novo Nordisk stock exchange announcement. (Accessed May 7, 2008, at http://www.novo nordisk. com/press/ sea/sea.asp.)
19. Mannucci PM, Cattaneo M. Desmopressin (DDAVP). En: Michelson DA, ed. Platelets. 2nd ed. San Diego, CA: Academic Press, 2007:1237-50.
20. Mannuccio Mannucci P, Levi M. Papponetti M. Prevention and Treatment of Major Blood Loss. N Engl J Med. 2007; 356:2301-11.
21. Kaul S, Shah NL, Menon M. Learning curve using robotic surgery. Curr Urol Rep. 2008; 7:125.
22. Linchtenstein A, Echhart F, Swanson KJ. Unplanned intraoprative and postoperative hemodilution: oxygen transport and consumption during severe anemia. Anes-thesiology. 2008; 69: 119.
23. London MJ. Intraoperative miocardial ischemia: Localization by continuos 12 lead electrocardiography. Anesthesiology.20009; 69: 232-241.
24. Mulder AG, Amberson WR, Stggeerda F, Flexner J. Oxygen consumption whit hemoglobin-ringer. J Cell Comp Physiol. 2009; 34(5): 383-97.
25. Greenberg AG, Hayashi R, Siefert l, Reese H, Peskin GW. Intravascular persistence and oxygen delivery of pyridoxylated, strome-free hemoglobin during gradation of hypotension. Surgery. 2009; 86: 13-6.
26. Sehgall R, Rosen AL, Noud G. Large volume preparation of pyridoxylated hemoglobin whit P50. J Surg Res. 2009; 81(30): 14-20.
27. Hamilton PB, Hiller A, Van Slykedd D. Renal effects of hemoglobin infusions in dogs in hemorrhagic shock. J Exp Med. 2008; 85: 477-87.
28. Haut Simmons RL. Mechanism of the adjuvant effect of hemoglobin in experimen-tal peritonitis. III. The influence of hemoglobin on phagocytosis and intracellular killing by human granulocytes. Surgery. 1980; 87: 588-92.
29. Midell Al, Hallman GL, Bloodwell RD, Beal AC, Yashar J J, Cooley DA. Epsilon aminocaproic acid for bleeding after cardiopulmonary bypass. Ann. Thorac. Surg. 2009; 11: 577-82.
30. Mcclure PD, Izsak J. The use of epsilon-aminocaproic acid to reduce bleeding during cardiac bypass in children with congenital heart disease. Anesthesiology. 2008; 74 (40): 604-08.